VistaGen Therapeutics (VTGN) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to VistaGen Therapeutics (VTGN) Misses Q2 EPS by 1c

Vistagen Reports Second Quarter Financial Results and Provides Corporate Update

November 10, 2022 4:30 PM EST

PALISADE-2 Phase 3 trial with PH94B in social anxiety disorder restart preparations underway after independent interim analysis recommends study continue as planned

Preliminary analysis of nearly 400 subjects in the final data set for the PALISADE Open Label Study demonstrates robust functional improvement in anxiety-provoking social and performance situations in daily life, as measured by the Liebowitz Social Anxiety Scale

Company planning to meet with the U.S. Food and Drug Administration regarding next step in Phase 3 development of PH94B in social anxiety disorder

... More